GlassScriptPhysician profile
Ricardo Gonzalez
NPI 1629020292
$313,819.66
in general payments reported to CMS, 2019-2025
39 companies · $3,911 in 2025
The $3,911 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141K · 2020: $39K · 2021: $37K · 2022: $14K · 2023: $34K · 2024: $45K · 2025: $3,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $25K · Travel and Lodging: $14K · Food and Beverage: $7,837 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,562.50 |
| Consulting Fee | $25,188.00 |
| Travel and Lodging | $14,241.70 |
| Food and Beverage | $7,837.47 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $242,311.85 | 2019-2025 | Greenlight Xps, Advantage System, Solyx Sis System |
| Procept Biorobotics Corporation | $56,035.86 | 2019-2025 | Aquabeam Robotic System, Aquabeam System |
| Allergan, INC. | $7,443.25 | 2019-2022 | |
| Medtronic, INC. | $2,839.76 | 2021-2025 | Interstim |
| Coloplast Corp | $1,058.49 | 2019-2023 | Coloplast Tfl Drive, Altis |
| Angiodynamics, INC. | $483.66 | 2023-2025 | Nanoknife, Solero |
| Abbvie INC. | $481.27 | 2019-2025 | |
| Axonics, INC. | $446.98 | 2020-2023 | Axonics |
| Olympus America INC. | $340.60 | 2021-2025 | Itind System |
| Medtronic USA, INC. | $303.86 | 2019-2020 | |
| Astellas Pharma US INC | $292.55 | 2019-2023 | Myrbetriq |
| Janssen Biotech, INC. | $173.50 | 2019-2024 | Erleada |
| Endo USA, INC. | $163.88 | 2024-2025 | Xiaflex, Aveed |
| Teleflex LLC | $160.49 | 2021-2022 | |
| Pfizer INC. | $140.09 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$276,774.17 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.